Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.782106
Keywords
NSCLC; immune checkpoint inhibitors; clinical benefit; prognosis; BRGPI
Categories
Funding
- National Key Basic Research Development Plan [2018YFC1312105]
- National Natural Science Foundation of China [81802299, 81502514]
- Graduate Innovation Funds of Peking Union Medical College [2019-1002-06]
- National Key R&D Program of China [2018YFC1312100, 2018YFC1312102]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001, 2017-I2M-1-005]
- Fundamental Research Funds for the Central Universities [3332018070]
Ask authors/readers for more resources
Immunotherapy has drawn significant attention in oncology, but traditional biomarkers for anti-PD-1 therapy may not be suitable for NSCLC clinical practice due to technical biases. The novel BRGPI, a gene expression-based index, showed strong potential as a predictive tool for identifying NSCLC patients who may benefit from anti-PD-1 immunotherapy, outperforming PD-L1 as a prognostic factor. Patients with low BRGPI and high PD-L1 levels were found to derive more clinical benefits from anti-PD-1 therapy.
Immunotherapy has been focused on by many oncologists and researchers. While, due to technical biases of absolute quantification, few traditional biomarkers for anti-PD-1 immunotherapy have been applied in regular clinical practice of non-small cell lung cancer (NSCLC). Therefore, there is an urgent and unmet need for a feasible tool-immune to data source bias-for identifying patients who might benefit from ICIs in clinical practice. Using the strategy based on the relative ranking of gene expression levels, we herein proposed the novel BRGP index (BRGPI): four BRGPs significantly related with progression-free survival of NSCLC patients treated with anti-PD-1 immunotherapy in the multicohort analysis. Moreover, stratification and multivariate Cox regression analyses demonstrated that BRGPI was an independent prognostic factor. Notably, compared to PD-L1, BRGPI exerted the best predictive ability. Further analysis showed that the patients in the BRGPI-low and PD-L1-high subgroup derived more clinical benefits from anti-PD-1 immunotherapy. In conclusion, the prospect of applying the BRGPI to real clinical practice is promising owing to its powerful and reliable predictive value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available